CBNGO00045: Key glycosyloxazoline tools for glycosylation studies 1072108-27-0

Chemical Information Common name: CBNGO00045 Chemical formula: C26H41N7O18 Molecular weight: 739.65 g/mol CAS number: 1072108-27-0 Category: Glycan Oxazoline Structural features CBNGO00045 is a carefully designed glycosyl oxazoline compound. The core of its structure lies in the construction of the oxazoline ring. This structural feature gives it unique chemical and biological properties: Highly reactive donor: The oxazoline ring structure makes it an efficient and stable active glycosyl donor. Catalyzed by specific enzymes, such as endoglycosidases, it transfers complex oligosaccharide chains to receptor molecules, such as proteins or peptides, in a highly controlled manner. Excellent enzymatic compatibility: This structure is an ideal substrate for a variety of endoglycosidases (Endoglycosidases) and their engineered mutants (such as Endo-S, Endo-F3 mutants), and is suitable for chemoenzymatic glycosylation strategies. Maintain natural linkages: Through the enzymatic transglycosylation reaction, N-glycoconjugates linked by β-1,4-glycosidic bonds that are completely consistent with the natural structure can be generated, avoiding the complex protection and deprotection steps in chemical synthesis, and having excellent site and stereoselectivity. Main applications and advantages Synthesis and engineering of homogenized glycoproteins In the field of biopharmaceuticals, the efficacy, stability and immunogenicity of protein drugs are closely related to their glycosylation modifications. CBNGO00045, as a core glycosyl donor, provides a powerful tool for the preparation of glycoproteins with uniform, well-defined N-glycan structures. Through enzymatic coupling, pre-synthesized, well-structured oligosaccharide chains can be precisely installed at specific sites on proteins to produce homogeneous glycoproteins for structural studies, functional identification, or drug development. Development of novel glycoconjugate vaccines and therapeutics Enzymatic glycosylation technology based on glycosyloxazolines opens the way for the development of a new generation of glycoconjugate vaccines and targeted therapies. Using compounds such as CBNGO00045, tumor- or pathogen-related specific oligosaccharide antigens can be coupled to carrier proteins or other immunostimulatory platforms efficiently and site-specifically, thereby inducing a powerful and specific immune response. This method can better maintain the antigenicity of sugar chains and achieve a more uniform product than traditional chemical coupling. Basic research and tool development in glycobiology Mechanism study: As a substrate analog of endoglycosidase, it can be used to study the catalytic mechanism, kinetics and specificity of the enzyme. Probes and Labels: This structure can be used to develop active site probes or labeling tools for glycosylation processes or sugar-protein interactions. Biomarker discovery: The defined glycosyloxazolines and their synthetic products help to establish standard methods for glycosylation analysis and identification, serving the screening and research of disease-related glycosylation biomarkers. Conclusion As a representative member of the glycosyloxazoline family, CBNGO00045's value lies in its ability to convert complex sugar chain chemistry into an efficient enzymatic bioconjugation process. From decoding glycosylation, a key post-translational modification mechanism, to promoting the development of homogeneous glycoprotein drugs and precision sugar vaccines, this compound has become an important bridge connecting glycochemistry and glycobiology, basic research and translational medicine. Its application in the fields of synthetic glycobiology and therapeutic glycoengineering continues to provide key technical support for understanding life processes and developing next-generation biomedicines. The above information is provided by the editor of Caisens Biology and is for scientific research only.